Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Nuwellis Inc (NUWE) Price & Performance

YieldMax AMD Option Income Strategy ETFTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

YieldMax AMD Option Income Strategy ETF vs Nuwellis Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.86, while Nuwellis Inc trades at $1.4 (market cap $542.80K). The key difference: YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.

AMDYNUWE
Sector
Income / Options OverlayTechnology
52-Week High
$59.52$220.50
52-Week Low
$29.80$1.42
Market Cap
$542.80K
Enterprise Value
-$1.27M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMD Option Income Strategy ETF

No Aura AI signal available yet.

Nuwellis Inc

NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.

Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax AMD Option Income Strategy ETF

AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.

Read more on AMDY

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE